Molecular Partners AG
SIX:MOLN
Molecular Partners AG
SIX:MOLN
Price:
3.35 CHF
-1.47%
Market Closed
Updated:
May 7, 2024
Molecular Partners AG
Cash from Operating Activities
|
Molecular Partners AG
Cash from Operating Activities Peer Comparison
Comparables:
ADCT
CRSP
BSLN
IDIA
KURN
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Cash from Operating Activities
-CHf59m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Cash from Operating Activities
-$118.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Cash from Operating Activities
-$260.4m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Cash from Operating Activities
CHf14.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Cash from Operating Activities
-CHf859.1m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Cash from Operating Activities
-CHf8.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
See Also
What is Molecular Partners AG's Cash from Operating Activities?
Cash from Operating Activities
-59m
CHF
-59m
CHF
Based on the financial report for Dec 31, 2023, Molecular Partners AG's Cash from Operating Activities amounts to -59m CHF.
What is Molecular Partners AG's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-27%
-27%
The average annual Cash from Operating Activities growth rates for Molecular Partners AG have been -27% over the past three years .
You don't have any saved screeners yet
